Amyotrophic Lateral Sclerosis Biomarker Assays

Contact us for further information!

We are continuously testing and developing new biomarker assays in the field of amyotrophic lateral sclerosis to support:

  • our validation of our disease models,
  • for additional counter-screening assays,
  • to improve predictivity in screening campaigns,
  • and to develop single assays to prescreen at lower costs.

We have performed a wide range of assays:

Viability Assays

Viability assays can be used to detect the potential capacity of a compound to prolong the survivability of cells. These assays can be combined with toxic agents or cells, such as pathological astrocytes, to amplify effects.


The Toxilight assay measures the adenylate kinase of damaged cells in supernatants. This is an easy and simple marker that can emphasize your results. We perform this assay in most projects as a control experiment. This assay can easily be combined with the MEA readout.


The Cell Titer Glo assay measures the quantity of ATP in lysates and correlates with the number of living cells. This assay can be performed with cells sourced from a MEA experiment.

Live Dead Assay

With the live-dead assay, the ratio of living cells to dead cells can be precisely determined. This assay requires well plates capable of imaging.

Inflammation Assays

Inflammation is supposed to play a role in amyotrophic lateral sclerosis. In co-culture experiments with astrocytes and/or microglia, inflammatory mechanisms can be modeled.


The blockade of IL1β is a potential target to stop ALS. The assay can be combined with MEA experiments.

Neurofilament Light Chain Assay

Neurofilament light chain is a diagnostic biomarker for ALS with blood samples. Therefore, an NF-L assay is an important biomarker that mimics clinical symptoms in a dish. Interestingly, the localization of NF-L at the initial axonal segment is connected to hyperexcitation.


The secretion of NF-L can be measured along with MEA experiments from supernatants.

Protein mislocalization or aggregation

Proteinopathies are the most discussed cornerstone of disease mechanisms in ALS.

TDP-43 mislocalization

TDP-43 mislocalization can be detected in disease cell lines of ALS models and quantitively assessed with our microscopic approaches.

Further ALS-relevant biomarkers are aberrant RNA homeostasis-causing stress granules or, in C9orf72 cells, dipeptide repeat proteins (DPR), which can be detected and quantified microscopically.

Target Validation

We have performed transcriptomics analysis for our assays. You can ask us for your gene of interest.

Ask us for new biomarker assays.

Contact us for further information!

Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics